Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $384000.0.

  • C4 Therapeutics' Depreciation and Depletion rose 520.55% to $384000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 3127.15%. This contributed to the annual value of $1.5 million for FY2024, which is 665.4% down from last year.
  • As of Q3 2025, C4 Therapeutics' Depreciation and Depletion stood at $384000.0, which was up 520.55% from $416000.0 recorded in Q2 2025.
  • C4 Therapeutics' 5-year Depreciation and Depletion high stood at $545000.0 for Q1 2023, and its period low was $128000.0 during Q4 2023.
  • For the 5-year period, C4 Therapeutics' Depreciation and Depletion averaged around $384736.8, with its median value being $384000.0 (2025).
  • Per our database at Business Quant, C4 Therapeutics' Depreciation and Depletion plummeted by 7543.19% in 2023 and then skyrocketed by 18437.5% in 2024.
  • Over the past 5 years, C4 Therapeutics' Depreciation and Depletion (Quarter) stood at $323000.0 in 2021, then surged by 61.3% to $521000.0 in 2022, then crashed by 75.43% to $128000.0 in 2023, then soared by 184.38% to $364000.0 in 2024, then rose by 5.49% to $384000.0 in 2025.
  • Its Depreciation and Depletion was $384000.0 in Q3 2025, compared to $416000.0 in Q2 2025 and $364000.0 in Q1 2025.